Last reviewed · How we verify

Bendamustine plus Rituximab — Competitive Intelligence Brief

Bendamustine plus Rituximab (Bendamustine plus Rituximab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating agent + monoclonal antibody combination. Area: Oncology.

phase 3 Alkylating agent + monoclonal antibody combination DNA (bendamustine); CD20 (rituximab) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Bendamustine plus Rituximab (Bendamustine plus Rituximab) — University of Giessen. Bendamustine chemotherapy damages cancer cell DNA while rituximab targets CD20 on B cells to enhance immune destruction of lymphoma cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Bendamustine plus Rituximab TARGET Bendamustine plus Rituximab University of Giessen phase 3 Alkylating agent + monoclonal antibody combination DNA (bendamustine); CD20 (rituximab)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alkylating agent + monoclonal antibody combination class)

  1. University of Giessen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Bendamustine plus Rituximab — Competitive Intelligence Brief. https://druglandscape.com/ci/bendamustine-plus-rituximab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: